Neurological Manifestations and Outcomes in a Retrospective Cohort of Mexican Inpatients with SARS-CoV-2 Pneumonia: Design of a Risk Profile

We analyzed the neurological manifestations in Mexican patients hospitalized with pneumonia due to COVID-19 and investigated the association between demographic, clinical, and biochemical variables and outcomes, including death. A retrospective, analytical study was conducted using the electronic re...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Silvia García, Francisco Manuel Cuatepotzo-Burgos, Christian Gabriel Toledo-Lozano, Adriana Balderrama-Soto, Sofía Lizeth Alcaraz-Estrada, Luis Montiel-López, Alberto Hilarión De la Vega-Bravo, Paul Mondragón-Terán, Maribel Santosbeña-Lagunes, Maricela Escarela-Serrano, Celia Mireya Rodríguez-Martínez, María del Carmen Méndez-Vidrio, Sandra Muñoz-López, José Alfredo Merino-Rajme, Rodrigo Alberto Rodríguez-Briseño, Fidel Cerda-Téllez, Ramón Mauricio Coral-Vázquez, Sergio Sauri-Suárez, Sandra Quiñonez-Aguilar, Juan Antonio Pineda-Juárez, Juan Antonio Suárez-Cuenca
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
R
Acceso en línea:https://doaj.org/article/4a05e40400f44e5fb838a2ab54c785a2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:We analyzed the neurological manifestations in Mexican patients hospitalized with pneumonia due to COVID-19 and investigated the association between demographic, clinical, and biochemical variables and outcomes, including death. A retrospective, analytical study was conducted using the electronic records of patients hospitalized between 1 April 2020 and 30 September 2020. Records of 1040 patients were analyzed: 31.25% died and 79.42% had neurological symptoms, including headache (80.62%), anosmia (32.20%), ageusia (31.96%), myopathy (28.08%), disorientation (14.89%), encephalopathy (12.22%), neuropathy (5.4%), stroke (1.3%), seizures (1.3%), cerebral hemorrhage (1.08%), encephalitis (0.84%), central venous thrombosis (0.36%), and subarachnoid hemorrhage (0.24%). Patients also had comorbidities, such as hypertension (42.30%), diabetes mellitus (38.74%), obesity (61.34%), chronic obstructive pulmonary disease (3.17%), and asthma (2.01%). Factors associated with neurological symptoms were dyspnea, chronic obstructive pulmonary disease, advanced respiratory support, prolonged hospitalization, and worsening fibrinogen levels. Factors associated with death were older age, advanced respiratory support, amine management, chronic obstructive pulmonary disease, intensive care unit management, dyspnea, disorientation, encephalopathy, hypertension, neuropathy, diabetes, male sex, three or more neurological symptoms, and obesity grade 3. In this study we designed a profile to help predict patients at higher risk of developing neurological complications and death following COVID-19 infection.